Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMI9PRJ)

• Drug Name: Diflorasone Drug Info
• Synonyms: Diflorasona; Diflorasonum; Maxiflor; Murode; U 34865; Diflorasona [INN-Spanish]; Diflorasone (INN); Diflorasone [INN:BAN]; Diflorasonum [INN-Latin]; Murode (TN); (6S,8S,9R,10S,11S,13S,14S,16S,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; (6alpha,11beta,16beta)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 6a,9a-difluoro-16b-methylprednisolone; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione

Indication

Disease Entry	ICD 11	Status	REF
Exanthem		Approved	[1]
Granuloma annulare		Approved	[1]
Primary cutaneous T-cell lymphoma		Approved	[1]
Rosacea	ED90.0	Approved	[2]

• Therapeutic Class: Antiinflammatory Agents
• Cross-matching ID:
  PubChem CID: 71415
  ChEBI ID: CHEBI:59750
  CAS Number: CAS 2557-49-5
  TTD Drug ID: DMI9PRJ
  INTEDE Drug ID: DR2429

Molecule-Related Drug Atlas

Drug(s) Targeting Phospholipase A2 (PLA2G1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[4]
Miltefosine	DMND304	Chronic urticaria		Approved	[5]
Clocortolone	DM9ZMQH	Exanthem		Approved	[6]
Clobetasol	DMUXP52	Rosacea	ED90.0	Approved	[7]
AllerB	DM78DOT	Allergy	4A80-4A85	Phase 2b	[8]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[9]
MANOALIDE	DMB4A8I	Arthritis	FA20	Phase 2	[10]
MRX-4	DMQZWYE	Allergic rhinitis	CA08.0	Phase 2	[11]
MRX-6	DMLVQKF	Contact dermatitis	EK0Z	Phase 2	[12]
Varespladib	DM5JJ83	Snakebite	N.A.	Phase 2	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phospholipase A2 (PLA2G1B)	TT9V5JH	PA21B_HUMAN	Inhibitor	[3]

References

• [1] Diflorasone FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Structures from powders: diflorasone diacetate. Steroids. 2009 Jan;74(1):102-11.
• [4] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [5] Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
• [6] Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980 Jan;25(1):96-8.
• [7] Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203.
• [8] Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):747-54.
• [9] Synthesis of benzoyl phenyl benzoates as effective inhibitors for phospholipase A2 and hyaluronidase enzymes. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4100-4.
• [10] Manoalide, a phospholipase A2 inhibitor, inhibits arachidonate incorporation and turnover in brain phospholipids of the awake rat. Neurochem Res. 1998 Oct;23(10):1251-7.
• [11] Phospholipase A2, group IVA (cytosolic, calcium-dependent) (PLA2G4A). SciBX 1(41); doi:10.1038/scibx.2008.999. Nov. 13 2008
• [12] A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5.
• [13] Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes. Toxins (Basel). 2022 Nov 11;14(11):783.